IL3 and cancer: This finding may be due to the fact that more than 30% of patients with solid malignant tumors have thrombocytosis, and pro-tumor growth cytokines within malignant tumor cells, such as IL-1, IL-3, and TNF-α, specifically stimulate platelet proliferation, resulting in an insignificant association between the PHR and stroke [62–64].